Pemetrexed or Nab-paclitaxel

ApprovedSmall molecule

SShanghai Pulmonary Hospital, Shanghai, China

Pemetrexed or Nab-paclitaxel is one of 53 small molecule programs targeting Lung Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerApproved

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Pemetrexed or Nab-paclitaxel

SShanghai Pulmonary Hospital, Shanghai, China

Approved

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

Vizimpro

Pfizer

Preclinical

4 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lung Cancer1 trial

Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer

Terminated·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04422392·93 enrolled

Non-Small Cell Lung Cancer1 trial

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer

Recruiting·TThe Affiliated Hospital of Qingdao University·Phase 4·NCT06357598·30 enrolled

Neoadjuvant Immunotherapy1 trial

Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT04943029·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pemetrexed or Nab-paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pemetrexed or Nab-paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pemetrexed or Nab-paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pulmonary Hospital, Shanghai, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShanghai Pulmonary Hospital, Shanghai, China

Pemetrexed or Nab-paclitaxel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lung Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Neoadjuvant Immunotherapy1 trial

References

Drug Info

Quick Facts

Related News